[HTML][HTML] Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape
JS Tregoning, KE Flight, SL Higham, Z Wang… - Nature reviews …, 2021 - nature.com
Where 2020 saw the development and testing of vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has …
syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented pace, the first half of 2021 has …
[HTML][HTML] COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …
challenge in this century. Two years after its emergence, the rapid development and …
[HTML][HTML] Clinical features of vaccine-induced immune thrombocytopenia and thrombosis
Background Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a new
syndrome associated with the ChAdOx1 nCoV-19 adenoviral vector vaccine against severe …
syndrome associated with the ChAdOx1 nCoV-19 adenoviral vector vaccine against severe …
[HTML][HTML] The use of viral vectors in vaccine development
T Travieso, J Li, S Mahesh, JDFRE Mello, M Blasi - npj Vaccines, 2022 - nature.com
Vaccines represent the single most cost-efficient and equitable way to combat and eradicate
infectious diseases. While traditional licensed vaccines consist of either …
infectious diseases. While traditional licensed vaccines consist of either …
[HTML][HTML] Epidemiology and prevention of venous thromboembolism
Venous thromboembolism, that consists of the interrelated conditions deep-vein thrombosis
and pulmonary embolism, is an under-appreciated vascular disease. In Western regions …
and pulmonary embolism, is an under-appreciated vascular disease. In Western regions …
[HTML][HTML] Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
Adenoviral vectors have been explored as vaccine agents for a range of infectious diseases,
and their ability to induce a potent and balanced immune response made them logical …
and their ability to induce a potent and balanced immune response made them logical …
[HTML][HTML] Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action
FX Heinz, K Stiasny - npj Vaccines, 2021 - nature.com
COVID-19 vaccines were developed with an unprecedented pace since the beginning of the
pandemic. Several of them have reached market authorization and mass production …
pandemic. Several of them have reached market authorization and mass production …
ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome
Vaccines derived from chimpanzee adenovirus Y25 (ChAdOx1), human adenovirus type 26
(HAdV-D26), and human adenovirus type 5 (HAdV-C5) are critical in combatting the severe …
(HAdV-D26), and human adenovirus type 5 (HAdV-C5) are critical in combatting the severe …
[HTML][HTML] Vaccine-induced immune thrombotic thrombocytopenia
In response to the COVID-19 pandemic, vaccines for SARS-CoV-2 were developed, tested,
and introduced at a remarkable speed. Although the vaccine introduction had a major …
and introduced at a remarkable speed. Although the vaccine introduction had a major …
[HTML][HTML] NETosis and neutrophil extracellular traps in COVID-19: immunothrombosis and beyond
Y Zhu, X Chen, X Liu - Frontiers in Immunology, 2022 - frontiersin.org
Infection with SARS-CoV-2, the causative agent of the Coronavirus disease 2019 (COVID-
19) pandemic, causes respiratory problems and multifaceted organ dysfunction. A crucial …
19) pandemic, causes respiratory problems and multifaceted organ dysfunction. A crucial …